FDA Updates Sotrovimab Emergency Use Authorization

Why It Matters

Removing sotrovimab eliminates a key monoclonal antibody option, reshaping COVID‑19 outpatient therapy and highlighting the need for variant‑responsive drugs.

Key Takeaways

• FDA fully revoked sotrovimab EUA nationwide April 5, 2022.
• BA.2 variant exceeds 50% prevalence in all HHS regions.
• Authorized dose ineffective against BA.2, per FDA fact sheet.
• Providers must switch to Paxlovid, Veklury, bebtelovimab, molnupiravir.
• Ongoing monitoring may affect future EUA decisions.

Pulse Analysis

Sotrovimab was one of the few monoclonal antibodies granted an Emergency Use Authorization early in the pandemic, offering a single‑infusion option for high‑risk patients with mild‑to‑moderate COVID‑19. Its efficacy hinged on the virus’s spike protein matching the antibody’s target, a condition that held true for earlier variants but eroded as Omicron’s BA.2 sub‑variant surged. By early 2022, CDC Nowcast data consistently showed BA.2 comprising over half of infections across all U.S. regions, prompting the FDA to reassess the drug’s clinical value.

The agency’s stepwise restriction—first limiting sotrovimab in specific states, then expanding the ban, and finally revoking the EUA entirely—illustrates a data‑driven regulatory approach. Health‑care providers were directed to pivot to alternative antivirals such as Pfizer’s Paxlovid, Merck’s Lagevrio, Gilead’s Veklury, and Eli Lilly’s bebtelovimab, all of which retain activity against BA.2. This shift not only safeguards patient outcomes but also reshapes prescribing patterns, supply chains, and reimbursement models for COVID‑19 therapeutics.

Beyond the immediate clinical impact, the sotrovimab revocation signals broader market implications. Companies developing monoclonal antibodies must now embed variant‑surveillance mechanisms into trial designs and manufacturing pipelines to avoid rapid obsolescence. Regulators, too, are likely to adopt more flexible EUA frameworks that can be swiftly updated as viral genetics evolve. For investors and policymakers, the episode underscores the premium placed on adaptable, broad‑spectrum antivirals in a landscape where viral mutation is the norm rather than the exception.